Skip to main content
Top
Published in: International Urology and Nephrology 3/2009

01-09-2009 | Urology - Original Paper

Effectiveness of totally tubeless percutaneous nephrolithotomy in selected patients: a prospective randomized study

Authors: Mustafa Okan Istanbulluoglu, Bulent Ozturk, Murat Gonen, Tufan Cıcek, Hakan Ozkardes

Published in: International Urology and Nephrology | Issue 3/2009

Login to get access

Abstract

Objectives

Compared with the standard technique, the number of percutaneous nephrolithotomy (PCNL) operations without a drainage catheter is increasing in recent years. In this prospective randomized study, we compared the morbidity of totally tubeless (tubeless and stentless) PCNL operations with the standard operation technique in a single center with a selected patient population.

Methods

Ninety patients who fulfilled the criteria were included. Forty-five patients underwent totally tubeless PCNL (Group 1) and a 14F malecot nephrostomy catheter was used in another set of 45 patients (Group 2). Inclusion criteria for the study were no serious bleeding or perforation in the collecting system during the operation, stone free or clinically insignificant residual fragments (CIRF <4 mm), and no more than one access.

Results

When two groups were compared with regard to age, stone volume, postoperative hemoglobin change, transfusion rate, and operation time, no significant differences were found between the two groups. However, a significant difference was found in hospitalization time between the two groups (P < 0.05). The amount of non-steroidal analgesic (tenoxicam) needed and non-steroidal analgesia-resistant pain which was resolved with narcotic analgesics (meperidine) were significantly lower in Group 1 (P < 0.05). Complications were observed in two patients (4.5%) in Group 1 (one retroperitoneal hematoma, one long-lasting renal colic) and in six patients (13.3%) in Group 2 (five prolonged urine drainage, one long-lasting fever) (P < 0.05).

Conclusions

Tubeless and stentless PCNL is a safe method and reduces hospitalization time and analgesic requirement, and promotes quality of life in selected patients.
Literature
5.
go back to reference Wickham JE, Miller RA, Kellett MJ et al (1984) Percutaneous nephrolithotomy: one stage or two? Br J Urol 56:582–585PubMedCrossRef Wickham JE, Miller RA, Kellett MJ et al (1984) Percutaneous nephrolithotomy: one stage or two? Br J Urol 56:582–585PubMedCrossRef
6.
go back to reference Winfield HN, Weyman P, Clayman RV (1986) Percutaneous nephrostolithotomy: complications of premature nephrostomy tube removal. J Urol 136:77–79PubMed Winfield HN, Weyman P, Clayman RV (1986) Percutaneous nephrostolithotomy: complications of premature nephrostomy tube removal. J Urol 136:77–79PubMed
7.
go back to reference Bdesha AS, Jones CR, North EA et al (1997) Routine placement of a nephrostomy tube is not necessary after percutaneous nephrostolithotomy. Br J Urol 79:1 Bdesha AS, Jones CR, North EA et al (1997) Routine placement of a nephrostomy tube is not necessary after percutaneous nephrostolithotomy. Br J Urol 79:1
15.
go back to reference Al-Ba’adani HT, Al-Kohlany KM, Al-Adimi A et al. (2007) Tubeless percutaneous nephrolithotomy: the new gold standard. Int Urol Nephrol 40:603–608 Al-Ba’adani HT, Al-Kohlany KM, Al-Adimi A et al. (2007) Tubeless percutaneous nephrolithotomy: the new gold standard. Int Urol Nephrol 40:603–608
Metadata
Title
Effectiveness of totally tubeless percutaneous nephrolithotomy in selected patients: a prospective randomized study
Authors
Mustafa Okan Istanbulluoglu
Bulent Ozturk
Murat Gonen
Tufan Cıcek
Hakan Ozkardes
Publication date
01-09-2009
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 3/2009
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-008-9517-6

Other articles of this Issue 3/2009

International Urology and Nephrology 3/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.